Karyopharm Therapeutics reported $46.24M in Gross Profit on Sales for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Gross Profit On Sales Change
TG Therapeutics TGTX:US 2.11M 373K
Abbott ABT:US $ 6908M 160M
Abbvie ABBV:US $ 9517M 1089M
Amgen AMGN:US $ 4677M 451M
Astrazeneca AZN:US 9.11B 169M
AstraZeneca AZN:LN 8.94B 2.9B
Biocryst Pharmaceuticals BCRX:US $ 49.68M 2.95M
Bristol Myers Squibb BMY:US $ 9177M 452M
Eli Lilly And LLY:US $ 5737.9M 211.8M
GlaxoSmithKline GSK:LN 6.14B 283M
Johnson & Johnson JNJ:US $ 15828M 1021M
Karyopharm Therapeutics KPTI:US $ 46.24M 79.28M
MacroGenics MGNX:US 11.05M 2.15M
Merk MRK:US $ 10567M 873M
Nektar Therapeutics NKTR:US $ 18.85M 0.76M
Novartis NOVN:VX 9.52B 3M
Novartis NVS:US $ 9059M 463M
Pfizer PFE:US $ 15651M 1516M
Regeneron Pharmaceuticals REGN:US $ 2560.2M 1408.9M
Takeda 4502:JP Y 564909M 54981M
Ultragenyx Pharmaceutical RARE:US $ 73.83M 6.04M
YTE INCY:US $ 696.02M 128.26M